209 patents currently held
78 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Feb 2027. from the record
Of the 78 now held by other companies, 64 name Knoa Pharma LLC as their current owner, and 14 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
53
Ending by 2030
Feb 2027
Next term end
129
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Aug 2027 · High confidence
Also notable
Ends Nov 2030 · High confidence
Also notable
Ends Aug 2032 · High confidence
Tamper Resistant Dosage Forms
US 8,815,289
Cited by 55 later US patents, top 10% of utility patents granted in 2014 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2027. A terminal disclaimer caps this term to an earlier patent's.
Compositions of Protein Receptor Tyrosine Kinase Inhibitors
US 9,040,508
Cited by 31 later US patents, top 25% of utility patents granted in 2015 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2030.
Pyrimidines as Sodium Channel Blockers
US 9,163,008
Cited by 30 later US patents, top 25% of utility patents granted in 2015 in our data, and renewed at every maintenance window due so far. Protection runs to 2032.
Formerly held, still cited
Notable
Ends Mar 2030 · High confidence
The most cited patent in this portfolio, cited by 270 later US patents, top 5% of utility patents granted in 2014 in our data. Protection runs to 2030.
now held by Knoa Pharma LLC
Also notable
Ends Dec 2031 · High confidence
Cited by 156 later US patents, top 5% of utility patents granted in 2014 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2031.
now held by Knoa Pharma LLC
Also notable
Ends Jun 2038 · High confidence
Cited by 21 later US patents, top 5% of utility patents granted in 2022 in our data. Protection runs to 2038.
now held by Knoa Pharma LLC
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Dec 16, 2026
- 2 fees due Jan 21 to 28, 2027 · next Jan 21
- 3 fees due Feb 4 to 28, 2027 · next Feb 4
- 6 fees due Mar 1 to 29, 2027 · next Mar 1
- 6 fees due Apr 6 to 27, 2027 · next Apr 6
- 3 fees due May 3 to 19, 2027 · next May 3
- 8 fees due Jun 5 to 30, 2027 · next Jun 5
- 4 fees due Jul 2 to 12, 2027 · next Jul 2
- 5 fees due Aug 4 to 27, 2027 · next Aug 4
- 5 fees due Sep 1 to 22, 2027 · next Sep 1
- 1 fee due Nov 3, 2027The maintenance fee for Opioid Dosage Forms Having Dose Proportional Steady State Cave and Auc and Less Than Dose Proportional Single Dose Cmax (US 9,326,959) comes due Nov 3, 2027. Unpaid by May 3, 2028, it lapses early.
Recent changes
- Oct 29Assignment recorded on 2 records: Huang, Haiyong Hugh and 1 other to Purdue Pharma L.P. Recorded Oct 29, 2026, executed Mar 4, 2020. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76554, frame 731.
- 2 terms have ended since Aug 16, 2026
What they patent
The 5 largest of its 129 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Methods and Compositions Particularly for Treatment of Attention Deficit Disorder | 12 in force | to Oct 2035 |
| Tamper Resistant Pharmaceutical Formulations | 8 in force | to Feb 2034 |
| Systems and Methods for Treating an Opioid-Induced Adverse Pharmacodynamic Response | 8 in force | to Apr 2033 |
| TRPV1 Antagonists Including Dihydroxy Substituent and Uses Thereof | 5 in force | to Jul 2030 |
| Substituted-Quinoxaline-Type Bridged-Piperidine Compounds as ORL-1 Modulators | 5 in force | to Jul 2029 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,790,689 | Tamper resistant transdermal dosage form In force · Medium confidence | In force | Medium confidence | |
| US 7,754,723 | Therapeutic Agents Useful for Treating Pain In force · High confidence | In force | High confidence | |
| US 7,790,215 | Sustained-Release Gel Coated Compositions In force · High confidence | In force | High confidence | |
| US 8,815,289 | Tamper Resistant Dosage Forms held by Purdue Pharma L.P. and Purdue Pharmaceuticals L.P. In force · High confidence | In force | High confidence | |
| US 9,492,390 | Tamper Resistant Dosage Forms held by Purdue Pharma L.P. and Purdue Pharmaceuticals L.P. In force · High confidence | In force | High confidence | |
| US 9,770,416 | Tamper Resistant Dosage Forms held by Purdue Pharma L.P. and Purdue Pharmaceuticals L.P. In force · High confidence | In force | High confidence | |
| US 8,778,382 | Tamper resistant transdermal dosage form In force · High confidence | In force | High confidence | |
| US 8,003,793 | Methods for Making 3-O-PROTECTED Morphinones and 3-O-PROTECTED Morphinone Dienol Carboxylates In force · High confidence | In force | High confidence | |
| US 7,767,699 | Therapeutic Agents Useful for Treating Pain In force · High confidence | In force | High confidence | |
| US 8,560,380 | Cycle Planning Tool with Event Conflict Resolution for Territory Management In force · High confidence | In force | High confidence |
Also on record, not counted in the 209: 78 patents in force now held by others · 289 patents ended · 26 applications pending · 253 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.